CNS biotech selling Auvelity for depression and developing/marketing other neuroscience drugs for narcolepsy and migraine.
CNS biotech selling Auvelity for depression and developing/marketing other neuroscience drugs for narcolepsy and migraine.
Sells prescription drugs in the US through its own sales team, with Auvelity leading sales and Sunosi bought from Jazz Pharmaceuticals in 2022. Prescription growth and insurer coverage, rather than price, drive revenue, and further sales depend on getting approval for additional uses of its existing drugs.
Moat: narrow (IP / patents, regulatory licence). A novel NMDA-receptor mechanism (Auvelity) is patent-protected and differentiated from standard antidepressants.
Headquarters: New York, New York, US · Founded: 2012 · Employees: 925
Size Axsome Therapeutics (AXSM) is a United States Health Care company (Biotechnology) with a market value of $7.05B, the 959th largest of 3,085 United States companies the cockpit tracks. Shares closed at $134.00 on 18 Nov 2026.
Performance Over six months the shares fell 41.9%, against +10.3% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 54.2% over the last twelve months (peer median +18.9%); the operating margin is -18.9% (peer median -11.5%).
Valuation It trades at 77.1× forward earnings against a peer median of 64.3× (4th most expensive of 8).
Short interest Short interest is 6.2% of the free float (30 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $865M | $638M | $386M | $271M | $50.0M |
| Revenue growth | — | +66% | +43% | +441% | — |
| Gross profit | $796M | $582M | $344M | $238M | $39.3M |
| EBITDA | -$153M | -$160M | -$244M | -$176M | -$170M |
| Net income | -$157M | -$183M | -$287M | -$239M | -$187M |
| Free cash flow | -$82.6M | -$93.9M | -$129M | -$146M | -$117M |
| Capital expenditure | $839,000 | $480,000 | $270,000 | $582,000 | $702,109 |
| Total debt | $224M | $218M | $203M | $186M | $94.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Axsome Therapeutics AXSM | $7.05B | -42% | +54% | -19% | 77.1× | n/a |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Otsuka Hldgs 4578.T | $39.9B | +9% | +11% | 18% | 16.8× | 1.6% |
| Jazz Pharmaceuticals Public JAZZ | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AXSM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.0% | -5.4% | 7th lowest of 21 |
| 6-month return | -41.9% | +10.3% | 3rd lowest of 21 |
| Distance from 52-week high | -48.5% | -32.6% | 4th lowest of 21 |
| Revenue growth (TTM) | +54.2% | +18.9% | 5th highest of 15 |
| Operating margin | -18.9% | -11.5% | 8th lowest of 16 |
| Forward P/E | 77.1× | 64.3× | 4th most expensive of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -19% | 77.1× | n/a | n/a |
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -4,294% | n/a | n/a | n/a |
| Immunovant IMVT | United States | $6.86B | -7% | n/a | n/a | n/a | n/a | n/a |
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -11% | n/a | 47.2% | +16.6% |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| Twist Bioscience TWST | United States | $7.93B | +117% | +22% | -29% | n/a | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | n/a | n/a | n/a |
| Summit Therapeutics SMMT | United States | $8.40B | -41% | n/a | n/a | n/a | n/a | n/a |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -71,732% | n/a | n/a | n/a |
| Genscript Biotech 1548.HK | Hong Kong | $8.69B | +133% | +53% | 12% | 294.1× | 36.9% | +19.8% |
| ALTEOGEN 196170.KS | South Korea | $8.80B | -56% | +61% | 53% | 42.0× | 24.6% | +38.5% |
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 13% | 79.4× | 18.2% | +61.5% |
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 35% | 64.3× | 36.9% | +26.2% |
| Vaxcyte PCVX | United States | $9.26B | +24% | n/a | n/a | n/a | n/a | n/a |
| Krystal Biotech KRYS | United States | $9.34B | +4% | +26% | 48% | 36.3× | 13.1% | +26.0% |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -210% | n/a | -6.5% | -10.0% |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.1B | +35% | 0% | 9% | 35.6× | 6.2% | +2.3% |
| Hangzhou Tigermed Consulting 300347.SZ | China | $4.88B | -2% | +16% | 10% | 97.0× | 25.9% | +16.4% |
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | n/a | n/a | n/a | n/a |
| Kymera Therapeutics KYMR | United States | $10.3B | +50% | +134% | -396% | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -8,684% | n/a | n/a | n/a |